Entrada director granted 19,000 stock options

Entrada Therapeutics director Bernhardt G. Zeiher received a grant of stock options covering 19,000 shares of common stock.

Rhea-AI Filing Summary

Entrada Therapeutics director Bernhardt G. Zeiher received a grant of stock options covering 19,000 shares of common stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. They vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.

Insights

Equity compensation analyst

Routine director stock option grant with long-dated expiration and standard vesting.

Director Bernhardt G. Zeiher was granted stock options for 19,000 shares of Entrada Therapeutics common stock at an exercise price of $5.97 per share. This award appears to be equity-based compensation rather than an open-market purchase or sale.

The options expire on June 10, 2036, providing long-term exposure to the company’s share price. Vesting occurs on the earlier of the one-year anniversary of June 10, 2026 or the next annual meeting of stockholders, so exercisability depends on that corporate calendar.

Following this grant, the filing shows 19,000 derivative securities held directly, with no additional derivative positions listed in this snapshot. As a compensation grant (Form 4 code A), it carries limited signaling value about the director’s short-term view on the stock.

Insider Trade Summary

Grant/Award: 19,000 shares

Grant/Award 1 txn

Insider Zeiher Bernhardt G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Key Figures

Option grant size: 19,000 shares Exercise price: $5.97 per share Expiration date: June 10, 2036 +2 more

5 metrics

Option grant size 19,000 shares Stock options granted to director on June 10, 2026

Exercise price $5.97 per share Strike price for granted stock options

Expiration date June 10, 2036 Option term end date

Underlying shares 19,000 shares Common stock underlying the options

Post-grant derivative holdings 19,000 derivative securities Total options held after this award

Key Terms

Stock Option (Right to Buy), Common Stock, Grant, award, or other acquisition, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Entrada Therapeutics (TRDA) director Bernhardt G. Zeiher report on this Form 4?

Director Bernhardt G. Zeiher reported receiving a grant of stock options for 19,000 shares of Entrada Therapeutics common stock. These options are a form of equity compensation, not an open-market stock purchase or sale, and are exercisable at a fixed price per share.

How many Entrada Therapeutics (TRDA) shares are covered by Zeiher’s new stock option grant?

The stock option grant covers 19,000 shares of Entrada Therapeutics common stock. Each option represents the right to buy one share at the specified exercise price, giving the director potential future ownership if the options are exercised after vesting conditions are met.

What is the exercise price and expiration date of Bernhardt Zeiher’s Entrada Therapeutics options?

The options have an exercise price of $5.97 per share and expire on June 10, 2036. This means Zeiher can choose to buy shares at $5.97, once vested, any time before the June 2036 expiration date, subject to the plan’s terms.

When do Bernhardt Zeiher’s Entrada Therapeutics stock options vest and become exercisable?

The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada Therapeutics’ next annual meeting of stockholders. Vesting must occur before the director can exercise the options and purchase common shares at the set price.

Is Bernhardt Zeiher’s Form 4 transaction in TRDA stock a market buy or sell?

No, the Form 4 transaction is a stock option grant coded as an acquisition (A), not a market buy or sell. It reflects equity compensation awarded by Entrada Therapeutics, giving Zeiher the right to purchase shares later rather than reporting an immediate stock trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeiher Bernhardt G

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.97	06/10/2026		A		19,000		(1)	06/10/2036	Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)